Innovent HK IPO gains wide support from international investors; Spearheads in cancer treatment breakthroughs

HONG KONG - (ACN Newswire) - Chinese biologic drug developer Innovent Biologics (Innovent) becomes the 4th pre-revenue biotech firm to list in Hong Kong yesterday. The seven-year-old...

Innovent Biologics Gets Listed Today; Long-term Bullish Performance Anticipated

HONG KONG - (ACN Newswire) - Innovent Biologics , a China Suzhou-based biopharmaceutical company, completes its initial public offering in Hong Kong, with trading officially...

Innovent Biologics Gets Listed Today; Long-term Bullish Performance Anticipated

HONG KONG - (ACN Newswire) - Innovent Biologics , a China Suzhou-based biopharmaceutical company, completes its initial public offering in Hong Kong, with trading officially commencing today....

Microbiome – The Next Frontier in Medicine

HONG KONG - (ACN Newswire) - Earlier this year the Hong Kong Exchange updated its listing rules to include pre-revenue biotech stocks for the first...

Ascletis Successfully Listed on the Main Board of HKEX

HONG KONG - (ACN Newswire) - Recently, following the official implementation of the revised listing rules by the Hong Kong Stock Exchange (HKEX), the Hong Kong capital...

Ascletis’ NDA for Its All-oral HCV Treatment Accepted by CFDA

Hangzhou and Shaoxing, China - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir...

Ascletis-developed Ganovo Acquired Extraordinary Achievement

Ganovo Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association HONG KONG - (ACN Newswire) - Ascletis announced on...